David Sinclair is targeting a rare but catastrophic side effect of blockbuster weight-loss drugs. His lab’s human trials aim to reverse blindness caused by GLP-1 medications like Ozempic, which are linked to NAION, a form of optic nerve stroke. The urgency isn't from high prevalence - NAION affects about 20,000 to 30,000 Americans yearly - but from the drug's massive user base and the potential for permanent damage.
On Moonshots with Peter Diamandis, Sinclair argued the goal is functional reversal, not just management. The gene therapy ER100 uses OSK transcription factors to reset the age of eye cells, a process shown in animals to regrow motor neurons. If biological age in the optic nerve can be rolled back, he contends, GLP-1 blindness might not be permanent.
"The link to GLP-1 use has created a new urgency for regenerative medicine."
- David Sinclair, Moonshots with Peter Diamandis
His lab’s ability to find this risk and a potential cure hinges on a new kind of AI. Sinclair describes an agentic system named Cadence that analyzed transcriptomic data and identified biological age markers humans had completely missed. It didn't just follow instructions; it made an independent discovery. This shifts AI from an automation tool to a creative scientific partner, screening billions of molecules for anti-aging properties in a process that would otherwise take centuries.
Parallel to the drug risk, Sinclair upended a core dogma of longevity. The long-standing view that lifestyle controls 90% of lifespan is wrong. Recent data suggests genetics and environment are closer to a 50/50 split. Peter Diamandis framed the hierarchy: lifestyle largely determines health until age 80, but the push from 80 to 110 is almost entirely gated by genetics.
"Lifestyle and behavior largely determine whether you reach age 80. However, the push from 80 to 110 is almost entirely gated by your genetic code."
- Peter Diamandis, Moonshots with Peter Diamandis
This doubling of genetics’ influence makes genomic sequencing a clinical necessity, not a curiosity. Sinclair argues doctors must now look at the genome to identify actionable risks before they manifest. The new frontier is using AI to overcome those genetic limits and reverse damage, whether from a rare drug side effect or from aging itself.
